Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy[2] Bezafibrate,
Ursodeoxycholic acid (UDCA)		[2] Ursodiol ,
Bezafibrate 💬 		[2] NR1H4,
PPARA 💬 		[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 94 💬
2Standard of Care: UDCA[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 93 💬
3UDCA[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[6] 46, 67, 93, 94, 97, 296 💬
4UDCA (Ursodeoxycholic acid)[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 93 💬
5Ursodeoxycholic acid (UDCA)[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 94 💬
6Ursodeoxycholic acid (UDCA) 500 mg[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 46 💬
7Ursodiol (ursodeoxycholic acid, UDCA)[1] Ursodeoxycholic acid (UDCA)[1] Ursodiol 💬 [1] NR1H4 💬 [1] Bile secretion 💬[1] 97 💬